"Cardiologists and cardiovascular and thoracic surgeons in greater Kansas City."

During the past decade, Midwest Heart and Vascular Specialists conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 9 clinical trials were completed, i.e. on average, 75% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 4 clinical trials were completed. i.e. 57.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Midwest Heart and Vascular Specialists" #1 sponsor was "Boehringer Ingelheim" with 4 trials, followed by "Point Biomedical" with 4 trials sponsored, "Pfizer" with 3 trials sponsored, "Amgen" with 2 trials sponsored and "Bristol-Myers Squibb" with 2 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Midwest Heart and Vascular Specialists" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "Duke Clinical Research Institute" with 2 trials as a collaborator, "Cardiovascular Research Foundation, New York" with 1 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator and "Pfizer" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Midwest Heart and Vascular Specialists" are "Coronary Artery Disease" (6 trials), "Coronary Artery Disease (CAD)" (3 trials), "Atrial Fibrillation" (2 trials), "Atrial Flutter" (2 trials) and "Healthy" (2 trials). Many other conditions were trialed in "Midwest Heart and Vascular Specialists" in a lesser frequency.

Most popular intervention types in "Midwest Heart and Vascular Specialists" are "Drug" (17 trials), "Other" (5 trials), "Procedure" (4 trials), "Behavioral" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Empagliflozin" (3 trials), "PB127 for Injectable Suspension" (3 trials), "200mg PF-04950615 (RN316)" (1 trials) and "300mg PF-04950615 (RN316)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Midwest Heart and Vascular Specialists" are 24 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are 6 active trials in "Midwest Heart and Vascular Specialists". 1 are not yet recruiting, 3 are recruiting, 1 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 14 completed trials in Midwest Heart and Vascular Specialists, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Midwest Heart and Vascular Specialists, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".